Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SXTP
Upturn stock ratingUpturn stock rating

60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)

Upturn stock ratingUpturn stock rating
$2.37
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: SXTP (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $7

1 Year Target Price $7

Analysts Price Target For last 52 week
$7Target price
Low$1.41
Current$2.37
high$16.92

Analysis of Past Performance

Type Stock
Historic Profit -69.53%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.39M USD
Price to earnings Ratio -
1Y Target Price 7
Price to earnings Ratio -
1Y Target Price 7
Volume (30-day avg) 1
Beta -
52 Weeks Range 1.41 - 16.92
Updated Date 06/30/2025
52 Weeks Range 1.41 - 16.92
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -21.94

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -745.61%

Management Effectiveness

Return on Assets (TTM) -89.53%
Return on Equity (TTM) -183.98%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 9658862
Price to Sales(TTM) 4.22
Enterprise Value 9658862
Price to Sales(TTM) 4.22
Enterprise Value to Revenue 14.51
Enterprise Value to EBITDA 22.23
Shares Outstanding 1472890
Shares Floating 1289266
Shares Outstanding 1472890
Shares Floating 1289266
Percent Insiders 4.97
Percent Institutions 7.3

Analyst Ratings

Rating 1
Target Price 7
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

60 Degrees Pharmaceuticals, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutics for infectious diseases. The company was founded in 2011 and is based in Cincinnati, Ohio. The company's primary focus has been on developing and commercializing drugs to prevent and treat infectious diseases.

business area logo Core Business Areas

  • Prevention and Treatment of Infectious Diseases: Focuses on developing and commercializing therapeutics and prophylactic measures for infectious diseases, particularly those relevant to travelers and global health.

leadership logo Leadership and Structure

The company is led by a management team with experience in pharmaceutical development and commercialization. The structure typically includes departments for research and development, clinical trials, regulatory affairs, manufacturing, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • Arakoda (tafenoquine): Arakoda is a prescription medicine used to prevent malaria. The market share for tafenoquine-based malaria prevention is growing, however specific figures are not publicly available. The drug competes with other malaria preventatives such as atovaquone-proguanil (Malarone), doxycycline, and mefloquine. Revenue from Arakoda is the primary revenue stream for 60 Degrees Pharma.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, specifically the segment focused on infectious diseases, is driven by global health concerns, travel-related illnesses, and emerging pathogens. This sector sees continuous research and development efforts to combat drug resistance and create new treatments.

Positioning

60 Degrees Pharmaceuticals, Inc. positions itself as a specialist in travel medicine and infectious disease prevention. Their advantage lies in their focus and specialized products.

Total Addressable Market (TAM)

The global market for malaria prevention and treatment is estimated to be in the billions of dollars. 60 Degrees Pharma is positioned to capture a segment of this market with Arakoda, particularly targeting travelers and military personnel. Exact figures depend on disease outbreak patterns and other variables.

Upturn SWOT Analysis

Strengths

  • Specialized focus on infectious diseases
  • Proprietary drug (Arakoda)
  • Established regulatory pathway for approval

Weaknesses

  • Limited product portfolio
  • Reliance on a single product for revenue
  • Smaller size compared to major pharmaceutical companies

Opportunities

  • Expanding into new geographic markets
  • Developing new drugs for other infectious diseases
  • Partnering with larger pharmaceutical companies

Threats

  • Competition from established malaria preventatives
  • Changes in travel patterns and disease prevalence
  • Regulatory hurdles for new drug approvals

Competitors and Market Share

competitor logo Key Competitors

  • Sanofi (SNY)
  • GlaxoSmithKline (GSK)
  • Novartis (NVS)

Competitive Landscape

60 Degrees Pharmaceuticals, Inc. faces strong competition from established pharmaceutical companies with broader product portfolios and larger distribution networks. Its advantage lies in its specialized focus and proprietary drug, Arakoda.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is difficult to assess due to the company being privately held. Growth is dependent on the success of Arakoda sales and any future product development.

Future Projections: Future growth is dependent on successful commercialization of Arakoda and potential new product developments. Projections are not publicly available.

Recent Initiatives: Recent initiatives likely include expanding marketing and distribution of Arakoda and pursuing research and development opportunities for new infectious disease therapeutics.

Summary

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on infectious diseases, primarily malaria prevention. Their main strength lies in their proprietary drug, Arakoda, but they face challenges due to their limited product portfolio and competition from larger companies. Opportunities exist in expanding into new markets and developing new drugs. Careful management of competition and regulatory hurdles is critical for future success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings of competitors
  • Industry reports

Disclaimers:

The information provided is based on publicly available data and may not be entirely accurate or complete. This analysis is not financial advice. Market share percentages are estimates.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About 60 Degrees Pharmaceuticals, Inc. Common Stock

Exchange NASDAQ
Headquaters Washington, DC, United States
IPO Launch date 2023-07-12
Chairman, CEO & President Dr. Geoffrey Stuart Dow Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 3
Full time employees 3

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.